Role of surgical resection for non-colorectal non-neuroendocrine liver metastases

Table 1 Summary of studies each of which included ≥ 100 patients who underwent hepatectomy for non-colorectal non-neuroendocrine liver metastases (overall survival)

Ref.	Year	Period	No. of patients	Primary tumor (GI/breast/GU/melanoma/sarcoma/others)	MST (mo)	3-ysr (%)	5-ysr (%)	Factors associated with worse overall survival
Elias et al[7]	1998	1984-1996	1201	(22/35/31/10/13/9)	NR	NR	362	NR
Yedibela et al[9]	2005	1978-2001	1501	(50/24/11/5/15/45)	232	NR	262	Margin status (R1,2)
Weitz et al[8]	2005	1981-2002	141	(12/29/50/17/0/33)	42	57	NR	Primary tumor type, disease-free interval ≤ 24 mo, margin status (R1,2)
Adam et al[10]	2006	1983-2004	1452	(314/460/332/148/0/198)	35	49	36	Age, primary tumor (ocular melanoma, non-breast), squamous tumor, disease-free interval, extrahepatic disease, major hepatectomy, margin status (R1,2)
Lendoire et al[11]	2007	1989-2006	106	(7/19/40/6/23/11)	27	34	19	Primary tumor (non-breast, non-GU), synchronous metastasis, margin status (R1,2)
O'Rourke et al[12]	2008	1986-2006	102	(27/11/31/20/3/10)	42	56	39	Diameter of liver metastasis > 5 cm, extrahepatic nodal disease
Groeschl et al[13]	2012	1990-2009	420	(13/15/92/31/98/71)	49	50	31	Diameter of liver metastasis ≥ 5 cm, lymphovascular invasion
Takemura et al[14]	2013	1993-2009	145	(91/30/12/1/8/3)	42	55	41	Postoperative complication
Hoffmann et al[15]	2015	2001-2012	150	(30/42/33/15/9/21)	46	NR	42	Primary tumor (melanoma, non-breast), interval < 24 mo, squamous tumor, non-stromal tumor, minor hepatectomy, margin (R2)
Schiergens et al[16]	2016	2003-2013	167	(43/16/61/8/25/14)	35	49	NR	> 3 liver metastases, extrahepatic disease, residual tumor (R1,2), major complications

¹Patients with neuroendocrine tumors were excluded;

²Results including neuroendocrine tumors. GI: Gastrointesti; GU: Genitourinary; MST: Median survival time; ysr: Year survival rate; NR: Not reported.